Anomer Bio

synthetic sugars to edit immunity and fibrosis

Company details

Glycans are complex sugars that coat proteins and dictate how cells and tissues behave. Glycan-driven mechanisms sit at the core of immune and fibrotic diseases and contribute to up to 25% of global disease burden, yet 96% of FDA-approved drugs target proteins.

Anomer Bio’s proprietary platform integrates multi-omics data, a Nobel Prize-winning research tool and insights from a first-in-class clinical trial to design synthetic sugar therapeutics. These small molecules are orally delivered, penetrate tissues deeply and selectively block the synthesis of disease-driving glycans. The platform has already yielded hit compounds that reprogram glycans better than the baseline for clinical testing.

Founded by researchers from the Francis Crick Institute and Oxford Dr Sophie James and Dr Marcos Burger Ramos, the company’s lead program focuses on Sanfilippo syndrome, a rare disorder caused by pathogenic glycan accumulation. Anomer Bio has secured $800k in dilutive and non-dilutive funding and is raising $1.2M to select a lead candidate ready for IND-enabling studies.

Get In Touch with Anomer Bio

Please tell us a little bit about yourself and why you'd like to get connected. Anomer Bio + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.